265 related articles for article (PubMed ID: 31217428)
21. Musashi2 modulates K562 leukemic cell proliferation and apoptosis involving the MAPK pathway.
Zhang H; Tan S; Wang J; Chen S; Quan J; Xian J; Zhang Ss; He J; Zhang L
Exp Cell Res; 2014 Jan; 320(1):119-27. PubMed ID: 24076374
[TBL] [Abstract][Full Text] [Related]
22. Developmental expression of Musashi-1 and Musashi-2 RNA-binding proteins during spermatogenesis: analysis of the deleterious effects of dysregulated expression.
Sutherland JM; Fraser BA; Sobinoff AP; Pye VJ; Davidson TL; Siddall NA; Koopman P; Hime GR; McLaughlin EA
Biol Reprod; 2014 May; 90(5):92. PubMed ID: 24671879
[TBL] [Abstract][Full Text] [Related]
23. HyperTRIBE uncovers increased MUSASHI-2 RNA binding activity and differential regulation in leukemic stem cells.
Nguyen DTT; Lu Y; Chu KL; Yang X; Park SM; Choo ZN; Chin CR; Prieto C; Schurer A; Barin E; Savino AM; Gourkanti S; Patel P; Vu LP; Leslie CS; Kharas MG
Nat Commun; 2020 Apr; 11(1):2026. PubMed ID: 32332729
[TBL] [Abstract][Full Text] [Related]
24. ADCY7 supports development of acute myeloid leukemia.
Li C; Xie J; Lu Z; Chen C; Yin Y; Zhan R; Fang Y; Hu X; Zhang CC
Biochem Biophys Res Commun; 2015 Sep; 465(1):47-52. PubMed ID: 26220344
[TBL] [Abstract][Full Text] [Related]
25. Natural product derivative Gossypolone inhibits Musashi family of RNA-binding proteins.
Lan L; Liu H; Smith AR; Appelman C; Yu J; Larsen S; Marquez RT; Wu X; Liu FY; Gao P; Gowthaman R; Karanicolas J; De Guzman RN; Rogers S; Aubé J; Neufeld KL; Xu L
BMC Cancer; 2018 Aug; 18(1):809. PubMed ID: 30097032
[TBL] [Abstract][Full Text] [Related]
26. The Msi Family of RNA-Binding Proteins Function Redundantly as Intestinal Oncoproteins.
Li N; Yousefi M; Nakauka-Ddamba A; Li F; Vandivier L; Parada K; Woo DH; Wang S; Naqvi AS; Rao S; Tobias J; Cedeno RJ; Minuesa G; Y K; Barlowe TS; Valvezan A; Shankar S; Deering RP; Klein PS; Jensen ST; Kharas MG; Gregory BD; Yu Z; Lengner CJ
Cell Rep; 2015 Dec; 13(11):2440-2455. PubMed ID: 26673327
[TBL] [Abstract][Full Text] [Related]
27. Differential regulation of the c-Myc/Lin28 axis discriminates subclasses of rearranged MLL leukemia.
Chen L; Sun Y; Wang J; Jiang H; Muntean AG
Oncotarget; 2016 May; 7(18):25208-23. PubMed ID: 27007052
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of LIN28B impairs leukemia cell growth and metabolism in acute myeloid leukemia.
Zhou J; Bi C; Ching YQ; Chooi JY; Lu X; Quah JY; Toh SH; Chan ZL; Tan TZ; Chong PS; Chng WJ
J Hematol Oncol; 2017 Jul; 10(1):138. PubMed ID: 28693523
[TBL] [Abstract][Full Text] [Related]
29. SYK inhibition targets acute myeloid leukemia stem cells by blocking their oxidative metabolism.
Polak A; Bialopiotrowicz E; Krzymieniewska B; Wozniak J; Stojak M; Cybulska M; Kaniuga E; Mikula M; Jablonska E; Gorniak P; Noyszewska-Kania M; Szydlowski M; Piechna K; Piwocka K; Bugajski L; Lech-Maranda E; Barankiewicz J; Kolkowska-Lesniak A; Patkowska E; Glodkowska-Mrowka E; Baran N; Juszczynski P
Cell Death Dis; 2020 Nov; 11(11):956. PubMed ID: 33159047
[TBL] [Abstract][Full Text] [Related]
30. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
[TBL] [Abstract][Full Text] [Related]
31. TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma.
Erazo T; Evans CM; Zakheim D; Chu KL; Refermat AY; Asgari Z; Yang X; Da Silva Ferreira M; Mehta S; Russo MV; Knezevic A; Zhang XP; Chen Z; Fennell M; Garippa R; Seshan V; de Stanchina E; Barbash O; Batlevi CL; Leslie CS; Melnick AM; Younes A; Kharas MG
Nat Commun; 2022 Sep; 13(1):5676. PubMed ID: 36167829
[TBL] [Abstract][Full Text] [Related]
32. Pharmacological targeting of miR-155 via the NEDD8-activating enzyme inhibitor MLN4924 (Pevonedistat) in FLT3-ITD acute myeloid leukemia.
Khalife J; Radomska HS; Santhanam R; Huang X; Neviani P; Saultz J; Wang H; Wu YZ; Alachkar H; Anghelina M; Dorrance A; Curfman J; Bloomfield CD; Medeiros BC; Perrotti D; Lee LJ; Lee RJ; Caligiuri MA; Pichiorri F; Croce CM; Garzon R; Guzman ML; Mendler JH; Marcucci G
Leukemia; 2015 Oct; 29(10):1981-92. PubMed ID: 25971362
[TBL] [Abstract][Full Text] [Related]
33. RNA-binding protein IGF2BP3 targeting of oncogenic transcripts promotes hematopoietic progenitor proliferation.
Palanichamy JK; Tran TM; Howard JM; Contreras JR; Fernando TR; Sterne-Weiler T; Katzman S; Toloue M; Yan W; Basso G; Pigazzi M; Sanford JR; Rao DS
J Clin Invest; 2016 Apr; 126(4):1495-511. PubMed ID: 26974154
[TBL] [Abstract][Full Text] [Related]
34. BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells.
Kawabata KC; Zong H; Meydan C; Wyman S; Wouters BJ; Sugita M; Goswami S; Albert M; Yip W; Roboz GJ; Chen Z; Delwel R; Carroll M; Mason CE; Melnick A; Guzman ML
Blood; 2021 Feb; 137(6):812-825. PubMed ID: 32911532
[TBL] [Abstract][Full Text] [Related]
35. Long non-coding RNA UCA1 modulates cell proliferation and apoptosis by regulating miR-296-3p/Myc axis in acute myeloid leukemia.
Li J; Wang M; Chen X
Cell Cycle; 2020 Jun; 19(12):1454-1465. PubMed ID: 32286143
[TBL] [Abstract][Full Text] [Related]
36. RNA binding protein Musashi-1 directly targets Msi2 and Erh during early testis germ cell development and interacts with IPO5 upon translocation to the nucleus.
Sutherland JM; Sobinoff AP; Fraser BA; Redgrove KA; Davidson TL; Siddall NA; Koopman P; Hime GR; McLaughlin EA
FASEB J; 2015 Jul; 29(7):2759-68. PubMed ID: 25782991
[TBL] [Abstract][Full Text] [Related]
37. Direct and indirect targeting of MYC to treat acute myeloid leukemia.
Brondfield S; Umesh S; Corella A; Zuber J; Rappaport AR; Gaillard C; Lowe SW; Goga A; Kogan SC
Cancer Chemother Pharmacol; 2015 Jul; 76(1):35-46. PubMed ID: 25956709
[TBL] [Abstract][Full Text] [Related]
38. Blast cells surviving acute myeloid leukemia induction therapy are in cycle with a signature of FOXM1 activity.
Williams MS; Basma NJ; Amaral FMR; Wiseman DH; Somervaille TCP
BMC Cancer; 2021 Oct; 21(1):1153. PubMed ID: 34711181
[TBL] [Abstract][Full Text] [Related]
39. PBX3 is an important cofactor of HOXA9 in leukemogenesis.
Li Z; Zhang Z; Li Y; Arnovitz S; Chen P; Huang H; Jiang X; Hong GM; Kunjamma RB; Ren H; He C; Wang CZ; Elkahloun AG; Valk PJ; Döhner K; Neilly MB; Bullinger L; Delwel R; Löwenberg B; Liu PP; Morgan R; Rowley JD; Yuan CS; Chen J
Blood; 2013 Feb; 121(8):1422-31. PubMed ID: 23264595
[TBL] [Abstract][Full Text] [Related]
40. Polo-like kinase 1 is overexpressed in acute myeloid leukemia and its inhibition preferentially targets the proliferation of leukemic cells.
Renner AG; Dos Santos C; Recher C; Bailly C; Créancier L; Kruczynski A; Payrastre B; Manenti S
Blood; 2009 Jul; 114(3):659-62. PubMed ID: 19458358
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
